← Back to headlines
Halozyme Stock Declines After Q4 Miss, Reaffirms 2026 Guidance
Halozyme's stock fell following a fourth-quarter earnings miss, though the company reiterated its guidance for 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
